Search
Filter Results
- Resource Type
- Book2
- Article1
- Atlases, Pictorial1
- Book Digital1
- Article Type
- Clinical Trial1
- Randomized Controlled Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Gastroenterology1
Search Results
Sort by
- BookKaren M. Facey, Helle Ploug Hansen, Ann N.V. Single, editors.Summary: "If you're not involving patients, you're not doing HTA!"--Dr. Brian O'Rourke, President and CEO of CADTH, Chair of INAHTA This is the first book to offer a comprehensive guide to involving patients in health technology assessment (HTA). Defining patient involvement as patient participation in the HTA process and research into patient aspects, this book includes detailed explanations of approaches to participation and research, as well as case studies. Patient Involvement in HTA enables researchers, postgraduate students, HTA professionals and experts in the HTA community to study these complementary ways of taking account of patients' knowledge, experiences, needs and preferences. Part I includes chapters discussing the ethical rationale, terminology, patient-based evidence, participation and patient input. Part II sets out methodology including: Qualitative Evidence Synthesis, Discrete Choice Experiments, Analytical Hierarchy Processes, Ethnographic Fieldwork, Deliberative Methods, Social Media Analysis, Patient-Reported Outcome Measures, patients as collaborative research partners and evaluation. Part III contains 15 case studies setting out current activities by HTA bodies on five continents, health technology developers and patient organisations. Each part includes discussion chapters from leading experts in patient involvement. A final chapter reflects on the need to clearly define the goals for patient involvement within the context of the HTA to identify the optimal approach. With cohesive contributions from more than 80 authors from a variety of disciplines around the globe, it is hoped this book will serve as a catalyst for collaboration to further develop patient involvement to improve HTA.
Contents:
1. Health Technology Assessment
2. Exploring Ethical Rationales
3. Reflections on Terms, Goals and Organisation
4. Patient-Based Evidence in HTA
5. Developing the Mosaic of Patient Participation in HTA
6. Patient Input to HTA
7. Discussion
Attending to Values and Quality of Patient Involvement in HTA
8. Patients as Collaborative Partners in Clinical Research to Inform HTA
9. Developing Patient-Reported and Relevant Outcome Measures
10. Discrete Choice Experiments
11. Analytic Hierarchy Process
12. Ethnographic Fieldwork
14. Deliberative Methods to Involve Patients in HTA
15. Qualitative Evidence Synthesis
16. Evaluation of Patient Involvement in HTA
17. Discussion
Making Sense of Patients' Perspectives, Experiences and Preferences in HTA
18. Discussion
Research to promote patient-based HTA
19. Australia
20. Brazil
21. Canada
22. Denmark
23. England
24. EUnetHTA
Patients' Perspectives in the HTA Core Model®
25. Germany
26. Italy
27. Scotland
28. Sweden
29. Taiwan
30. USA
Comparative Effectiveness Research
31. Discussion of Approaches in Different Countries
32. Discussion
Patient Participation in HTA; Evidence of Real Change?
33. Patient Involvement in Medicine Development and Assessment
34. Medical Technologies: Involving Patients in Development and Assessment
35. Role of Patient Organisations
36. Discussion
Perspective of an HTA Appraisal Committee Chair
37. Reflections for Future Development. - ArticleWinship DH.Gastroenterology. 1978 Feb;74(2 Pt 2):402-6.The published world literature on the efficacy of cimetidine, a histamine H2-receptor antagonist, in the treatment of duodenal ulcer is reviewed. In eight prospective randomized double blind placebo-controlled studies, cimetidine was administered to 348 duodenal ulcer patients with an incidence of endoscopically verified healing incidence of 37 percent in 300 placebo-treated patients. Healing rates were similar in patients receiving cimetidine in doses ranging from 0.8 to 2.0 g per day. It appears that at least 3 to 4 weeks of cimetidine therapy are needed to achieve healing rates of about 70 percent. In most trials, cimetidine was superior to placebo in achieving symptom relief in patients with duodenal ulcer. The drug has not been shown to result in acid rebound after cessation of therapy. There are no published prospective studies on the question of whether treatment with cimetidine results in increased ulcer for the short term treatment of duodenal ulcer. More data are required for an assessment of long term therapy with cimetidine.